HC Wainwright Issues Positive Estimate for PTGX Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Research analysts at HC Wainwright upped their Q1 2026 EPS estimates for shares of Protagonist Therapeutics in a research note issued to investors on Thursday, February 26th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.70) per share for the quarter, up from their previous estimate of ($0.71). HC Wainwright has a “Buy” rating and a $117.00 price objective on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q2 2026 earnings at $1.98 EPS, Q3 2026 earnings at $3.60 EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at $4.18 EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($2.08) EPS, FY2029 earnings at $0.12 EPS and FY2030 earnings at $1.22 EPS.

PTGX has been the topic of a number of other research reports. Weiss Ratings cut shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. Citizens Jmp increased their price objective on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a research report on Thursday. JPMorgan Chase & Co. lifted their price target on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Jefferies Financial Group boosted their price objective on Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Finally, Citigroup upped their target price on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.31.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $92.08 on Monday. The stock’s 50 day moving average is $84.24 and its 200 day moving average is $77.16. Protagonist Therapeutics has a one year low of $35.97 and a one year high of $96.54. The firm has a market cap of $5.88 billion, a P/E ratio of -44.92 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The business had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.

Insider Buying and Selling

In related news, Director Lewis T. Williams sold 18,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $644,936.50. This represents a 69.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Arturo Md Molina sold 5,000 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total transaction of $410,000.00. Following the completion of the sale, the insider directly owned 84,115 shares in the company, valued at approximately $6,897,430. The trade was a 5.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 203,167 shares of company stock valued at $16,889,199. Corporate insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada boosted its position in shares of Protagonist Therapeutics by 30.6% during the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock valued at $482,000 after acquiring an additional 2,334 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Protagonist Therapeutics by 0.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after buying an additional 348 shares during the last quarter. Millennium Management LLC boosted its stake in Protagonist Therapeutics by 283.6% in the first quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after buying an additional 99,269 shares in the last quarter. CWM LLC grew its holdings in shares of Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after purchasing an additional 407 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Protagonist Therapeutics by 37.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,903 shares of the company’s stock worth $216,000 after purchasing an additional 1,071 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Company news: Reported Rusfertide NDA filing and a shift in the rusfertide collaboration that market commentary says materially improves commercialization clarity and near-term value capture; this news is cited as the primary driver of an ~11% intraday move. Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift
• Positive Sentiment: Analyst optimism: A published note raised a price target to $100, signaling increased analyst conviction and helping lift sentiment. Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $100.00
• Positive Sentiment: Additional price-target upgrade: Another report pushed a higher target to $113, reinforcing the momentum from analyst re-ratings. Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00
• Neutral Sentiment: HC Wainwright stance: The firm reiterated a “Buy” rating with a $117 target and materially increased its FY‑2026 EPS estimate to $4.18, reflecting expectations for near‑term revenue/cash flow improvement tied to pipeline events—this supports the positive view but is tempered by other estimate changes below.
• Negative Sentiment: Mixed/longer‑term estimate cuts: HC Wainwright issued multiple downward revisions to FY‑2027 through FY‑2030 and trimmed several quarterly estimates (notably lower FY‑2027 and FY‑2028 EPS forecasts and a sharp cut to FY‑2030 from prior levels), which could temper enthusiasm about long‑range earnings power and leave upside dependent on execution and approval/commercial details.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.